NEW YORK, Nov. 26, 2004 (PRIMEZONE) -- The following is an investment opinion issued by Investrend Research Syndicate:
Investrend Research analyst Ryan C. Fuhrmann, CFA has initiated Criterion research coverage on Power3 Medical Technology (OTCBB:PWRM), rating it a "Speculative/3."
"Power3 Medical Products, Inc. is an advanced proteomics company that applies years of proprietary methodologies to discover and identify protein biomarkers associated with disease," said Fuhrmann.
Other report highlights:
"The Company's focus on 3-4 main product development arenas represent huge markets and could lead to additional markets.
"By comparing proteins of healthy individuals with diagnosed patients, Power3 can accurately identify which protein species are involved in a disease and identify potential protein targets for use in diagnostic tests or for therapeutic intervention.
"The company is continually enhancing its competitive position with 300 identified and 500+ in-evaluation biomarkers of human disease and operates a state-of-the-art proteomics laboratory in The Woodlands, Texas.
"Recently, PWRM obtained exclusive rights to a test that analyzes nipple aspirate fluids (NAF) which are obtained from the breast utilizing a modified breast pump.
"Power3 also entered into a research agreement with the Baylor College of Medicine (BcoM) to identify biomarkers capable of detecting certain neurodegenerative diseases such as Lou Gehrig's disease (ALS), Alzheimer's disease (AD), and Parkinson's disease.
"PWRM is in the development stage and has no material revenue. As such, the Company's value lies in its future cash flows and these are hard to predict. In fact, despite its huge potential, the entire proteomics facet of the biotechnology industry is a development-stage technology with little commercial success to date.
"Investment in PWRM is speculative at this point in time but appears to offer potential for those interested in investing in a start-up company with a focus on the proteomics industry," Fuhrmann concluded.
The analyst's credentials are at http://www.investrend.com/articles/secondlevel.asp?level=238
Enrollment in standards-based research is an important measure of a company's commitment to transparency and Good Governance. Investrend Research's pioneering program facilitates independent analysts to provide coverage for shareholders in companies that otherwise would have little or no analyst following. Investrend subscribes to the "Standards for Independent Research Providers" at http://www.firstresearchconsortium.com. Enrollment fees for Criterion coverage are $10,940, and the fees were paid by the company. Analysts are paid in advance of initial reports by Investrend Research to eliminate pecuniary interest, and neither the analyst nor employees of Investrend Research may own or trade stocks of companies under coverage.
Complete information is available at the company's InvestorPower page at http://www.investrend.com/company/list.asp?sPathParam=yes, and the full report is available at www.investrendresearch.com. Investors are advised to read disclosures carefully before trading in the equities of any enrolled company.
Anyone interested in receiving alerts regarding Power3 research should email contact@investrend.com with "PWRM" in the subject line.
Power3 Medical Products, Inc., 3400 Research Forest Drive, Suite B2-3, The Woodlands, TX 77381 Web site: http://www.power3medical.com/default.aspx